U.S. FDA Grants Tentative Approval of YUTREPIA™ ( treprostinil ) Inhalation Powder for Patients with Pulmonary Arterial Hypertension ( PAH ) and Pulmonary Hypertension Associated with Interstitial Lung Disease ( PH-ILD ) - Liquidia ( NASDAQ:LQDA )
FDA confirmed that the amendment to add PH-ILD to the YUTREPIA NDA was proper and that application otherwise meets the requirements for approval under the Federal Food, Drug, and Cosmetic Act Final Approval of YUTREPIA for PAH and PH-ILD may occur after expiration of 3-year regulatory exclusivity ...
| Ticker |
Sentiment |
Impact |
|
LQDA
|
Somewhat Bullish
|
21 %
|
|
UTHR
|
Neutral
|
8 %
|
